Top Line: Today we dive into an urology-led investigation of just how bad late genitourinary side effects can be following prostate radiation.
The Study: To answer this, of course, we must go straight to the source: the men sick enough to land in the emergency room. The IRRADIaTE registry prospectively enrolled 321 Italian men with localized prostate cancer previously treated with curative, adjuvant, or salvage external beam radiation who later developed late (>6 months) genitourinary complications requiring urgent medical attention. This is the key framing device, and the key limitation. By design, this is not a denominator study of post-radiation toxicity–as can be easily misconstrued–but rather a case series of the side effect profiles. The results state: 43% presented with CTCAE grade 3–5 toxicity at admission, hospitalization-free survival dropped from 86% at 1 year to 42% at 5 years, and the proportion avoiding major surgery declined steadily over time. Patients receiving definitive versus adjuvant radiation appeared to fare worse, though baseline age and comorbidity differences loom large.
TBL:IRRADIaTE compellingly describes what severe late GU toxicity looks like once it declares itself and should inform multidisciplinary rescue pathways but not be misconstrued as a referendum on the risks of prostate radiation across a population. | Bertolo, Eur Urol Oncol 2026
The Study: To answer this, of course, we must go straight to the source: the men sick enough to land in the emergency room. The IRRADIaTE registry prospectively enrolled 321 Italian men with localized prostate cancer previously treated with curative, adjuvant, or salvage external beam radiation who later developed late (>6 months) genitourinary complications requiring urgent medical attention. This is the key framing device, and the key limitation. By design, this is not a denominator study of post-radiation toxicity–as can be easily misconstrued–but rather a case series of the side effect profiles. The results state: 43% presented with CTCAE grade 3–5 toxicity at admission, hospitalization-free survival dropped from 86% at 1 year to 42% at 5 years, and the proportion avoiding major surgery declined steadily over time. Patients receiving definitive versus adjuvant radiation appeared to fare worse, though baseline age and comorbidity differences loom large.
TBL:IRRADIaTE compellingly describes what severe late GU toxicity looks like once it declares itself and should inform multidisciplinary rescue pathways but not be misconstrued as a referendum on the risks of prostate radiation across a population. | Bertolo, Eur Urol Oncol 2026